
Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen
TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits... » read more